Quality indicators measuring pharmaceutical care for asthma and chronic obstructive pulmonary disease within primary care: a scoping review

Clicks: 8
ID: 328404
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #152 of 189 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 189 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: Despite the growing emphasis on quality improvement, an overview of quality indicators (QIs) measuring pharmaceutical care in asthma and COPD remains limited. Numerous QIs have been developed for general respiratory care, yet often designed for physician-led hospital settings rather than pharmacist-led primary care. This scoping review provides an overview of existing QIs measuring pharmaceutical care for asthma and COPD within primary care, including an evaluation of their clinimetric properties. METHODS: A systematic literature search was conducted across five electronic databases. The population included adult asthma and/or COPD patients; concept aimed at QIs measuring structures, processes, and outcomes; in the context of pharmaceutical care provided by pharmacists in primary care. Selected articles were categorized using a two-stage approach; a study-level classification followed by an indicator-level classification of identified QIs. RESULTS: Of the 46 articles identified 23 articles (47.9%) focused on development, 16 articles (33.3%) on validation, and 9 articles on feasibility (18.8%). Overall, 188 QIs measuring pharmaceutical care for asthma and/or COPD were identified, categorized into five healthcare domains; 1) screening and diagnosis (10.6%), 2) guideline-based pharmacological treatment (21.8%), 3) self-management support (25.0%), 4) referral for expert advice (7.4%) and 5) disease control assessment (35.1%). Identified QIs included structure (1.6%), process (81.9%) and outcome (16.5%). 155 QIs (82.4%) were evaluated on development-related metrics, 46 QIs (24.5%) on validation and 42 QIs (22.3%) on feasibility. CONCLUSION: A vast overview of QIs have been identified for pharmaceutical care in asthma and COPD, noting their practical utility and validation depends on their applicability for internal clinical improvement or external 'pay-for-performance' schemes.
Reference Key
openalex_W7212285230 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Claire D. Visser, Henk-Jan Guchelaar, Martina Teichert
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag277
URL
https://doi.org/10.1093/ajhp/zxag277
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.